Contenido analtico verificado: 50,7 mg Nivel de endotoxinas inferior a 0,001 EU/mg
[5] The authors concluded that survodutide is generally tolerable in people with compensated or decompensated cirrhosis, does not require pharmacokinetic-based dose adjustment for cirrhosis, and may improve liver-related non-invasive tests supporting further investigation for MASH-related cirrhosis while remaining early-stage, small-sample, open-label evidence
Potential Side Effects There is a possibility of adverse reactions due to unregulated ingredients
While promising in various experimental contexts, much remains under investigation, and findings continue to evolve
J Immunol Res (2023) 2023:8929525
Throughout this article, both names are used interchangeably